MARKET

CBIO

CBIO

Catalyst Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.780
-0.005
-0.10%
Opening 10:34 09/23 EDT
OPEN
4.820
PREV CLOSE
4.785
HIGH
4.842
LOW
4.774
VOLUME
11.96K
TURNOVER
--
52 WEEK HIGH
7.55
52 WEEK LOW
3.720
MARKET CAP
149.93M
P/E (TTM)
-1.5894
1D
5D
1M
3M
1Y
5Y
Here's Why We're A Bit Worried About Catalyst Biosciences' (NASDAQ:CBIO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 6d ago
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Wednesday, September 15, 2021 at 1:00 pm Eastern Time.
GlobeNewswire · 09/15 12:00
Catalyst up 12% on platform study on CFI proteases for immune system benefit
Catalyst Biosciences (NASDAQ:CBIO) shares are up 12% in premarket trading after unveiling data that will be presented today at a medical conference on its proprietary ProTUNE platform. The platform is able to
Seekingalpha · 09/10 12:58
CEI, CEMI and CBIO among pre market gainers
IVERIC bio (NASDAQ:ISEE) +65% Apellis' mixed eye-drug data turns out to be 'positive' for Iveric Bio Vince Holding (NYSE:VNCE) +22% on Q2 earnings. Affirm Holdings (NASDAQ:AFRM) +21% on Q4 earnings. Endo International (NASDAQ:ENDP) +18% settles New
Seekingalpha · 09/10 12:16
Apellis' mixed eye-drug data turns out to be 'positive' for Iveric Bio
Apellis Pharmaceuticals (NASDAQ:APLS) shares extended yesterday's losses, down 33% premarket after the company reported mixed results from late-stage pegcetacoplan studies. The company's eye medicine designed to treate geographic atrophy (GA), a leading
Seekingalpha · 09/10 11:09
Catalyst Biosciences Announces Oral, Poster Presentations At International Conference On Complement Therapeutics
Catalyst Biosciences, Inc. (NASDAQ:CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021.   The oral presentation, "Complement Factor I
Benzinga · 09/09 12:13
Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021. The oral presentation, “Compl...
GlobeNewswire · 09/09 12:00
Stonepine Capital Management, LLC Buys Amryt Pharma PLC, CTI BioPharma Corp, Chiasma Inc, Sells ...
GuruFocus News · 08/24 15:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBIO. Analyze the recent business situations of Catalyst Biosciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBIO stock price target is 16.60 with a high estimate of 18.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 22.08M
% Owned: 70.39%
Shares Outstanding: 31.37M
TypeInstitutionsShares
Increased
17
1.98M
New
10
957.92K
Decreased
29
3.35M
Sold Out
30
1.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.94%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Non-Executive Chairman/Independent Director
Augustine Lawlor
President/Chief Executive Officer/Director
Nassim Usman
Chief Financial Officer
Clinton Musil
Senior Vice President
Tom Knudsen
Chief Scientific Officer
Grant Blouse
Director
Jeanne Jew
Independent Director
Errol De Souza
Independent Director
Andrea Hunt
Independent Director
Geoffrey Ling
Independent Director
Sharon Tetlow
Independent Director
Edward Williams
Declaration Date
Dividend Per Share
Ex-Div Date
08/04/2015
Dividend USD 0.5692
08/20/2015
About CBIO
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.